Q32 Bio Inc.

QTTB Healthcare Biotechnology

Q32 Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.7 million.

EPS
+43.6%
Free cash flow
+71.1%
Total debt
−35.6%

Quarter to June 2026, against a year earlier

9.25 0.40 +4.52%
Market cap
$263.5M
P/E
3.1×
Fwd P/E
−6.2×
Dividend yield
—
F-score
n/a
Altman Z
−0.78
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
20.30 5.36 4.85 4.57
Net Debt/EBITDA
11.68 5.60 4.99 5.08
Debt/Equity
0.00 0.18 0.23 (0.61)
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.15) (0.45) 0.07 (0.35)
Book value per Share
5.21 3.29 3.42 (1.51)
Free Cash Flow
(3.07) (6.34) 0.82 (4.23)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026